Virtonomy
Virtonomy provides a digital twin platform (v-Patients) that enables cardiovascular medical device developers to perform virtual implantation, anatomical analysis, and regulatory-grade simulations across thousands of virtual patients, reducing development timelines and animal testing.
- Company typePrivate
- Founded2019
- HeadquartersMunich, Germany
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Virtonomy does
Virtonomy is a Munich-based digital health company that provides a digital twin and medical simulation platform, branded as v-Patients, for cardiovascular medical device development. The platform enables medical device developers to perform virtual implantation, anatomical analysis, and performance simulations across thousands of virtual patients built from real clinical imaging data, replacing or reducing reliance on physical prototyping and animal testing. Its core technology combines AI-powered anatomical segmentation of CT, MRI, X-ray, and ultrasound DICOM data, proprietary DICOM-to-3D model conversion, statistical shape modeling for worst-case and edge-case anatomies, and a Smoothed Particle Hydrodynamics (SPH) meshless simulation method for fluid dynamics and structural mechanics, with NVIDIA GPU acceleration delivering up to 650% speedup over CPU baselines.
The platform is delivered through a tiered architecture: the core v-Patients web product for virtual cohort selection and 3D visualization, add-on modules for statistical shape modeling, AI coronary anatomical analysis, and simulation services spanning fluid dynamics, structural mechanics, device deployment, and performance modeling. Revenue is generated through quote-based enterprise subscriptions with multi-year contracts, cohort-specific virtual patient database access, and professional services for advanced simulation execution and regulatory consultation. The company serves cardiovascular medical device developers (heart valves, stents, catheters, cannulas, occluders, TAH, heart assist devices) and regulatory affairs teams, with a direct enterprise field sales motion anchored by free regulatory consultation workshops and device-specific demonstrations. Named enterprise customers include Boston Scientific, Medtronic, Biotronik, Getinge, Abiomed, RealHeart, Evaheart, Medira, NVT, and Intershunt. Regulatory positioning is a core commercial lever, with methods validated against ASME V&V 40 and ISO 5840, digital evidence accepted by FDA and EU regulatory bodies, and an ex-FDA advisor (Dr. Tina Morrison) supporting credibility. The company is incorporated as Virtonomy GmbH, founded around 2019, and has raised approximately $3.85M in disclosed funding led by Accenture Ventures in 2023.
Virtonomy firmographics
Firmographics- Name
- Virtonomy
- Legal name
- Virtonomy GmbH
- Website
- https://virtonomy.io
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Virtonomy provides a digital twin platform (v-Patients) that enables cardiovascular medical device developers to perform virtual implantation, anatomical analysis, and regulatory-grade simulations across thousands of virtual patients, reducing development timelines and animal testing.
- Ownership category
- akta.pro rank
Virtonomy industry classification
Industry- Product category
- Medical Device Simulation Software
- NAICS
- Software Publishers (513210)
- SIC
- Services-Prepackaged Software (7372), Services-Health Services (8000)
- akta.pro primary industry
- Digital Twins & Scenario-Based Systems Training (Equipment/Process Simulators) (EDAFAJAJ)
- akta.pro secondary industry
- Healthcare & Clinical Simulation (Surgery, Nursing, EMT, Patient Interaction) (EDAFAJAC)
Keywords
Where Virtonomy is headquartered
LocationHeadquarters
- HQ city
- Munich
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Virtonomy business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- v-Patients SaaS Platform Subscription: Subscription-based access to the v-Patients digital twin platform for virtual patient selection, 3D model access, and simulation capabilities. Pricing likely tiered by cohort size and simulation complexity.
- Simulation Services: Professional services for advanced anatomical simulations including fluid dynamics, structural mechanics, device deployment, and performance modeling. Customers control simulations while Virtonomy handles technical difficulties.
- Regulatory Consultation Services: Expert regulatory services including virtual testing plan drafting, FDA/EU compliance consultation, and validated virtual evidence report generation for regulatory submissions.
- Cohort-Specific Virtual Patient Database Access: Access to curated virtual patient cohorts tailored to specific device types, pathologies, and demographic requirements for anatomical analysis and device fit validation.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Custom enterprise licensing with quote-based pricing |
| Other | Multi-year contract | Professional services for simulation and regulatory consultation |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels7 records
Virtonomy product offering
Product offeringCore offering
Virtonomy sells the v-Patients platform, an end-to-end digital twin and simulation solution that lets cardiovascular medical device developers perform virtual implantation, anatomical analysis, and validated simulations on thousands of virtual patients built from real clinical data. The offering combines a SaaS software platform with professional anatomical simulation services and FDA/EU regulatory consultation, supported by a proprietary database of 3D patient models and AI-powered automated device positioning.
Product overview
Virtonomy offers v-Patients as a unified digital twin and simulation platform for medical device development, consisting of a core web-based platform complemented by specialized modules: a virtual patient cohort database containing thousands of 3D anatomical models, advanced statistical shape modeling for worst-case and edge-case analysis, anatomical simulation services covering fluid dynamics and structural mechanics, and regulatory consultation services for FDA/EU compliance. The platform enables medical device developers to perform virtual implantation and testing across diverse patient populations, replacing traditional physical testing with validated in silico evidence.
Differentiator
Problem solved
Functional benefit
Brands
- v-Patients: Virtonomy's virtual trial platform featuring digital patient twins for medical device development, enabling virtual implantation, simulation, and testing across patient populations.
Products and services
- v-Patients
Quantifiable outcome
- Development timeline reduction from years to weeks
- +5 more outcomes
Companies that use Virtonomy
Customer profileNamed customers13 records
Segments3 records
Ideal customer profiles2 records
Virtonomy technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability9 records
Feature8 records
Virtonomy partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- NVIDIAcoreStrategic technology partnership leveraging NVIDIA AI infrastructure (L40S GPU on EC2 g6e instances) to enhance simulation performance. Achieved 650% speedup for high-resolution biomedical simulations. Collaboration enables GPU-accelerated coronary simulations, AI anatomical computation, and integration with NVIDIA Omniverse for digital twin environments.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Virtonomy competitors and assessment
Company assessmentDirect peers
- Dassault Systèmes (Living Heart Project): Dassault Systèmes' Living Heart Project is the most direct competitor to Virtonomy, offering FDA-validated cardiovascular digital twin simulations for medical device development through the 3DEXPERIENCE platform. Both target heart valve, TAH, and cardiovascular implant developers with virtual patient testing and regulatory evidence generation.
- FEops: FEops provides cardiovascular simulation software (HEARTguide) for structural heart device planning and TAVR/LAAC procedures using patient-specific digital twins. It is a direct competitor to Virtonomy in the cardiovascular in silico device testing space, particularly for heart valves and occluders.
- InSilicoTrials: InSilicoTrials operates a cloud platform aggregating validated in silico models for medical device and drug development, competing directly with Virtonomy's regulatory-focused simulation and virtual evidence services. Both target the same enterprise medtech customers with simulation-as-a-service offerings.
- HeartFlow: HeartFlow builds cardiovascular digital twins from CT imaging for FFR-CT analysis and coronary disease diagnosis, with overlap to Virtonomy's cardiovascular digital twin and AI-powered coronary analysis capabilities. Both leverage deep-learning image segmentation and validated computational models in cardiology.
- Simpleware (Synopsys): Simpleware, now part of Synopsys, provides medical image segmentation and 3D model generation software used widely in medical device R&D. It directly overlaps with Virtonomy's DICOM processing pipeline and anatomical segmentation capabilities for cardiovascular and broader device development.
Broad incumbents
- Ansys: Ansys is a broad simulation incumbent whose Ansys Discovery and Ansys LS-DYNA platforms are used in medical device design, fluid-structure interaction, and regulatory submissions. It competes with Virtonomy in computational mechanics for cardiovascular implants but from a general-purpose simulation position rather than a cardiovascular-specialist one.
- Siemens Healthineers (Digital Twin / Heart Center): Siemens Healthineers offers digital twin capabilities across cardiovascular imaging and device planning through its Healthineers portfolio. It overlaps with Virtonomy in cardiovascular imaging-based digital modeling but as part of a much broader medical imaging and diagnostics franchise.
- Materialise: Materialise provides 3D medical imaging software (Mimics) and patient-specific anatomical modeling for surgical planning and medical device development. It competes with Virtonomy's DICOM-to-3D model pipeline and anatomical analysis modules, particularly for cardiovascular and orthopedic applications.
Emerging players
- Unlearn.AI: Unlearn.AI builds digital twin prognostic twins for clinical trial design and patient outcome prediction in pharma and biotech. It overlaps with Virtonomy's in silico trial thesis but focuses on drug trials and prognostic modeling rather than cardiovascular device testing.
- Q Bio: Q Bio builds whole-body digital twin platforms from quantitative MRI for clinical insights and preventive health. It is an emerging player in the broader medical digital twin space, thematically comparable to Virtonomy's patient-twin approach but focused on diagnostic imaging rather than device development.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Virtonomy social profiles
Digital presenceVirtonomy compliance and trust
Trust signalCompliance5 records
Virtonomy financial estimates
Financial estimateRevenue estimate
Valuation estimate
Virtonomy leadership team
Management profileNumber of profiles
Profiles2 records
Virtonomy funding detail
Funding detailFunding overview
Funding rounds3 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Virtonomy M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Virtonomy
What does Virtonomy do?
Virtonomy sells the v-Patients platform, an end-to-end digital twin and simulation solution that lets cardiovascular medical device developers perform virtual implantation, anatomical analysis, and validated simulations on thousands of virtual patients built from real clinical data. The offering combines a SaaS software platform with professional anatomical simulation services and FDA/EU regulatory consultation, supported by a proprietary database of 3D patient models and AI-powered automated device positioning.
Is Virtonomy a public or private company?
Virtonomy is a private company. It is classified as venture growth investor backed and is currently operating.
When was Virtonomy founded?
Virtonomy was founded in 2019. It employs 11 to 50 people.
Where is Virtonomy based?
Virtonomy is headquartered in Munich, Germany, in the Europe region.
How does Virtonomy make money?
Four revenue lines are on record. v-Patients SaaS Platform Subscription is the primary driver. The others are simulation Services, regulatory Consultation Services and cohort-Specific Virtual Patient Database Access.
Who are Virtonomy's main competitors?
Direct peers on record are Dassault Systèmes (Living Heart Project), FEops, InSilicoTrials, HeartFlow and Simpleware (Synopsys). Broad incumbents are Ansys, Siemens Healthineers (Digital Twin / Heart Center) and Materialise. Emerging players are Unlearn.AI and Q Bio.
Does Virtonomy have an API?
No public API is recorded for Virtonomy.
What industry is Virtonomy in?
Virtonomy's product category is Medical Device Simulation Software. Its primary akta.pro industry code is EDAFAJAJ, Digital Twins & Scenario-Based Systems Training (Equipment/Process Simulators), with a secondary code of EDAFAJAC, Healthcare & Clinical Simulation (Surgery, Nursing, EMT, Patient Interaction). Its NAICS code is 513210 and its SIC code is 7372.